Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed that it repurchased 100,300 H-shares on 15 July 2026 via the Hong Kong Stock Exchange at prices ranging between HKD 19.43 and HKD 20.12, with a volume-weighted average cost of HKD 19.88 per share. The transaction totalled HKD 1.99 million and the repurchased shares have been retained as treasury stock.

Prior to the buyback, Bao Pharma had 153.39 million issued shares (excluding 0.94 million treasury shares). The latest transaction reduced the outstanding share count by 0.07 million shares, representing 0.07% of the pre-event float, and lifted treasury holdings to 1.04 million shares. The company’s total issued share capital remains unchanged at 154.33 million shares, as the repurchased shares have not been cancelled.

The buyback forms part of the mandate approved by shareholders on 26 May 2026, which permits the company to repurchase up to 15.43 million shares. Including the recent trade, Bao Pharma has acquired 1.04 million shares, equivalent to 0.67% of the shares outstanding on the mandate date. Under Hong Kong listing rules, the company is subject to a moratorium on new share issues or treasury-share sales until 14 August 2026.

Board authorisation and regulatory compliance confirmations accompanied the disclosure, indicating adherence to the Hong Kong Stock Exchange’s Main Board Rules and relevant legal requirements.